睿智医药9月30日获融资买入916.92万元，融资余额2.03亿元

Core Insights - The stock of Ruizhi Pharmaceutical experienced a decline of 0.78% on September 30, with a trading volume of 119 million yuan [1] - The company reported a net financing outflow of 13.11 million yuan on the same day, with a total financing and securities balance of 203 million yuan [1][2] - For the first half of 2025, Ruizhi Pharmaceutical achieved a revenue of 534 million yuan, representing a year-on-year growth of 14.75%, and a net profit of 25.38 million yuan, up 140.35% year-on-year [2] Financing and Trading Activity - On September 30, the financing buy-in amount for Ruizhi Pharmaceutical was 9.17 million yuan, while the financing repayment was 22.28 million yuan, resulting in a net financing buy-in of -13.11 million yuan [1] - The current financing balance of 203 million yuan accounts for 3.58% of the circulating market value, which is above the 70th percentile of the past year [1] - The company had a securities lending balance of 4,200 shares, with a total value of 47,900 yuan, which is below the 20th percentile of the past year [1] Shareholder and Dividend Information - As of September 20, the number of shareholders for Ruizhi Pharmaceutical was 44,700, a decrease of 5.99% from the previous period, while the average circulating shares per person increased by 6.37% to 10,626 shares [2] - Since its A-share listing, the company has distributed a total of 180 million yuan in dividends, with no dividends paid in the last three years [3] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 24.33 million shares, unchanged from the previous period [3]